Precipio, Inc. Common Stock (PRPO)

Price$22.10

Value ScoreC

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-16.17%

Price vs S&P 500 (4W)-15.48%

VGM Score61.08

Market Capitalization$39.50M

All Metrics

P/CF (Annual)57.67x

Book Value / Share (Quarterly)$7.94

P/TBV (Annual)11.05x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)36.72%

Cash Flow / Share (Quarterly)$0.31

Price vs S&P 500 (YTD)-12.60%

Gross Margin (TTM)43.71%

Net Profit Margin (TTM)-3.57%

EPS (TTM)$-0.51

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-0.51

Revenue Growth (5Y)31.61%

EPS (Annual)$-0.23

ROI (Annual)-2.33%

Gross Margin (Annual)44.52%

Net Profit Margin (5Y Avg)-57.84%

Cash / Share (Quarterly)$1.46

Revenue Growth QoQ (YoY)36.15%

ROA (Last FY)-1.70%

Revenue Growth TTM (YoY)28.97%

EBITD / Share (TTM)$-0.13

ROE (5Y Avg)-37.62%

Operating Margin (TTM)-6.30%

Cash Flow / Share (Annual)$0.20

P/B Ratio2.79x

P/B Ratio (Quarterly)3.15x

Net Income / Employee (Annual)$-6,000

EV / Revenue (TTM)1.47x

Net Interest Coverage (TTM)-3.97x

ROA (TTM)-4.49%

EV / EBITDA (TTM)101.26x

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)1.61x

Quick Ratio (Quarterly)1.33x

3-Month Avg Trading Volume0.03M

52-Week Price Return99.64%

EV / Free Cash Flow (Annual)105.49x

Revenue / Employee (TTM)$423,500

Tangible BV / Share (Quarterly)$1.95

P/S Ratio (Annual)1.64x

Asset Turnover (Annual)1.13x

52-Week High$33.63

Operating Margin (5Y Avg)-60.16%

EPS Excl Extra (Annual)$-0.23

CapEx CAGR (5Y)16.80%

Tangible BV CAGR (5Y)-8.92%

26-Week Price Return-7.99%

Quick Ratio (Annual)1.28x

13-Week Price Return-23.20%

Total Debt / Equity (Annual)0.07x

Current Ratio (Quarterly)1.56x

Enterprise Value$37.87M

Revenue / Share Growth (5Y)15.07%

Asset Turnover (TTM)1.26x

Book Value / Share Growth (5Y)-12.63%

Revenue / Employee (Annual)$394,200

Inventory Turnover (Annual)16.09x

Pretax Margin (Annual)-1.51%

Cash / Share (Annual)$1.49

3-Month Return Std Dev64.00%

Gross Margin (5Y Avg)35.72%

Net Income / Employee (TTM)$-15,100

ROE (Last FY)-2.49%

Net Interest Coverage (Annual)-13.63x

EPS Basic Excl Extra (Annual)$-0.23

P/FCF (TTM)65.94x

Receivables Turnover (TTM)17.43x

EV / Free Cash Flow (TTM)68.23x

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-0.51

Receivables Turnover (Annual)17.28x

ROI (TTM)-6.28%

P/S Ratio (TTM)1.53x

Pretax Margin (5Y Avg)-57.78%

Revenue / Share (Annual)$14.98

Tangible BV / Share (Annual)$2.04

Forward P/E0.81x

Price vs S&P 500 (52W)76.78%

Year-to-Date Return-3.83%

5-Day Price Return-3.91%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-28.81%

Net Profit Margin (Annual)-1.51%

Month-to-Date Return-3.07%

Cash Flow / Share (TTM)$-6.37

EBITD / Share (Annual)$0.23

Operating Margin (Annual)-4.40%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)49.81x

ROI (5Y Avg)-36.15%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.51

P/TBV (Quarterly)12.80x

P/B Ratio (Annual)2.77x

Inventory Turnover (TTM)17.16x

Pretax Margin (TTM)-3.57%

Book Value / Share (Annual)$8.18

Price vs S&P 500 (13W)-34.56%

Beta1.35x

P/FCF (Annual)110.03x

Revenue / Share (TTM)$14.49

ROE (TTM)-6.73%

52-Week Low$10.50

vGradeC

gGradeA

mGradeC

vgmGradeB

Show chart for

Analyst Recommendations

Mar 2024

Apr 2024

May 2024

Jun 2024

4.14

Industry Peers — Lab Analytical Instruments(24)

Symbol	Value Score	Growth Score	Momentum Score	Price
PRPOPrecipio, Inc. Common Stock	C	A	C	$22.10
AAgilent Technologies Inc.	C	C	C	$129.84
WATWaters Corp	D	C	B	$355.53
ILMNIllumina Inc	D	D	A	$160.97
MTDMettler-Toledo International	D	C	C	$1131.49
RVTYRevvity, Inc.	C	D	B	$99.66
BRKRBruker Corporation	D	D	B	$54.23
BIOBio-Rad Laboratories, Inc.Class A	C	F	B	$285.94
BIO.BBio-Rad Laboratories, Inc. Class B	C	F	B	$304.15
AVTRAvantor, Inc.	B	D	C	$9.39
TXG10x Genomics, Inc. Class A Common Stock	D	C	A	$28.84

About

Precipio Inc develops blood cancer diagnostics designed to reduce misdiagnoses among office-based oncologists. The company operates CLIA-certified laboratories in Connecticut and Nebraska, offering diagnostic products including HemeScreen and IV-Cell to healthcare providers across the United States. Revenue is primarily generated from third-party payers.